On October 27, Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd. announced that the U.S. Food and Drug Administration approved LOQTORZI (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The active ingredient in LOQTOZI, toripalimab, is a monoclonal antibody that binds programmed death receptor-1 (PD-1) and blocks its interactions with ligands PD-L1 and PD-L2 with high potency, enabling the immune system to activate and kill the tumor. According to the press release, LOQTORZI is the first and only FDA-approved agent for NPC patients. LOQTORZI is expected to be available in the United States in Q1 2024.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
